<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524810</url>
  </required_header>
  <id_info>
    <org_study_id>CAPYTTOLE</org_study_id>
    <nct_id>NCT00524810</nct_id>
  </id_info>
  <brief_title>Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer</brief_title>
  <official_title>A Multi-center Phase II Study Evaluating the Efficacy and Tolerance of the Association of Liposomal Doxorubicin and Docetaxel in First Line Chemotherapy in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin
      + Docetaxel in patients with metastatic breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin
      + Docetaxel in patients with metastatic breast cancer. Patients will receive pyridoxin to
      prevent cutaneo-mucinous toxicities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-progression rate after 6 cycles</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tolerance and toxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response and duration</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Caelyx - Taxotere</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin</intervention_name>
    <description>Caelyx 30 mg/m² day 1 every 3 weeks</description>
    <arm_group_label>Caelyx - Taxotere</arm_group_label>
    <other_name>Caelyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Taxotere 75 mg/m² day 2 every 3 weeks</description>
    <arm_group_label>Caelyx - Taxotere</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first metastatic chemo line

          -  presence of measurable or bone lesion

          -  at least one lesion outside the radiated areas

          -  can have previously received hormonotherapy, chemotherapy in adjuvant phase,
             radiotherapy if older than 4 weeks

        Exclusion Criteria:

          -  only local tumoral progression

          -  symptomatic cerebral metastasis

          -  neuropathy &gt; NCI-CTC 2

          -  previous cancer within 10 years _ previous cancer within 10 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laure CHAUVENET, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital HOTEL DIEU - Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital HOTEL DIEU</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <last_update_submitted>June 29, 2011</last_update_submitted>
  <last_update_submitted_qc>June 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Douglas Micheau</name_title>
    <organization>ARCAGY-GINECO</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

